Reyes-Gómez U, Cruz-García LG, Arista-Viveros A, López-Cruz G, Garzón-Sánchez E, Colón-Cuesta F

Language: Spanish
References: 18
Page: 27-30
PDF size: 35.55 Kb.

ABSTRACT

The Streptococcus pneumoniae or pneumococcus, causes serious infections in children ranging from pneumonia, sepsis and meningitis. Across the time, pneumococcal has shown increasing resistance to antimicrobials classics. One of the best strategies of prevention are the vaccines. Our country counts with 2, one Valent polysaccharide conjugate indicated primarily for children under 2 years and another 23 serotypes for older children. The emerging presence of other serotypes that cause disease and are not contained in the current vaccine, forcing the need for new vaccines containing these. Basic aspects of these changes and their potential impact will be discussed.

REFERENCES

1. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization. WHO position paper. Weekly Epidemiological Record. 2007; 82: 93-104.

2. Morbidity and Mortality Weekly Report 2009; 58: 1.

3. Arredondo GJ, Castañón GJ, Domínguez SL, García PE, Granados AJ, Guinto BG, Heinze MG, Hernández GM y cols. Enfermedades neumocócicas en niños. Presentación clínica y tratamiento Boletín de información clínica y terapéutica Academia Nacional de Medicina 2009; 18(2): 1-5.

4. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005; 5: 83-93.

5. Siber GR, Klugman KP, MakaelaPH, editors.Pneumococcal vaccines.The impact of conjugate vaccine. Washington DC: ASM Press; 2008.

6. Oosterhuis- Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of neumococcal conjugate vaccines (1998- 2006). Vaccine. 2007; 25: 194-212.

7. Esposito S, Pugni L, Bosis S, Proto A, Cesati L, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3,5 and 11 months post-natally to pre and full-term infants. Vaccine 2005; 23 (14): 1703-8.

8. Ulloa- Gutiérrez R, Ávila- Aguero ML. 6th International Synposium on Pneumococci and Pneumococcal Diseases. Expert Rev Vaccines. 2008; 7: 725-8.

9. Salleras L. La emergencia de serotipos no vacunales en la enfermedad neumocócica: un probable origen multifactorial. Vacunas 2008;9 (Supl 1): 3- 11.

10. Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. The Pneumococcal Carriage Group (PneumoCarr). Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines. 2006; 5: 651-68.

11. Pelton SI.Replacement pneumococcal disease in perspective.Clin Infect Dis. 2008; 46: 1353-5.

12. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serptypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007; 297: 1784-92.

13. Centers for Disease Control and Prevention.Invasive pneumococcal disease in children 5 years a fter conjugate vaccine introduction -Eight States, 1998-2005.MMWR. 2008; 57: 144-8.

14. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of childen with 7 valentpneumoccal conjugate vaccine on incidence of invasive pneumoccal disease. 1United States, 1998-2003 MMWR 2005; 54: 893-7.

15. Ruiz CJ. Vacunas neumococicas conjugadas: Presente y futuro Enf Infec Microbiol Clin 2008; 26 (supl 1): 48-55.

16. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven - valent pneumococcal disease: a matched case-control study. Lancet. 2006; 368: 1495-502.

17. Grijalva CG, Griffin MR. Population -based impact of routine infant immunization with neumococcal conjugate vaccine in the USA. Expert Rev. Vaccines. 2008; 7: 83-95.

18. Hernández PM. Impacto de la inmunización con la vacuna conjugada de neumococo. (editl) Rev Enf Infec Ped 2009; 87: 67.